The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Utilization and clinical practice impact of an interactive tool for guiding choice of systemic adjuvant treatment (adj TX) for patients with early breast cancer (EBC).
P. Ravdin
Consultant or Advisory Role - Adjuvant, Inc.
Stock Ownership - Adjuvant, Inc.
S. Martino
No relevant relationships to disclose
M. D. Pegram
Consultant or Advisory Role - Eisai; GlaxoSmithKline; Roche/Genentech; Sanofi ; Takeda
Honoraria - Eisai; GlaxoSmithKline; Roche/Genentech; Sanofi ; Takeda
Research Funding - Sanofi
Expert Testimony - Novartis
Other Remuneration - Pfizer
N. J. Robert
Consultant or Advisory Role - Pfizer; Roche; Sanofi
Honoraria - Roche; Sanofi
Research Funding - Pfizer
S. M. Swain
Consultant or Advisory Role - Eisai (U); Novartis (U); Roche/Genentech (U); Sanofi (U)
Research Funding - Bristol-Myers Squibb; Genentech; Pfizer
Other Remuneration - Sanofi
D. Janssen
Employment or Leadership Position - Clinical Care Options
A. Bowser
Employment or Leadership Position - Clinical Care Options
J. A. Mortimer
Employment or Leadership Position - Clinical Care Options
Stock Ownership - Clinical Care Options
R. W. Carlson
Consultant or Advisory Role - Genentech (U); Pfizer